REMSleep Holdings Inc. has announced the passing of its founder, Thomas Wood, and the subsequent appointment of Jeffrey Marshall as Chief Executive Officer, marking a pivotal transition for the medical device company as it prepares to commercialize its flagship sleep apnea treatment. Wood, who founded the company and served as Chairman and CEO, passed away on February 26, 2026, after a career dedicated to developing innovative solutions for sleep apnea patients, holding 26 patents for CPAP interface components.
The company's Board of Directors has been reconstituted to ensure continuity, with Anita Michaels, Wood's sister and the company's Chief Operating Officer, elected as Chairman. According to Michaels, Wood was a visionary who spent years building REMSleep from the ground up, securing funding, achieving FDA 510(k) clearance for the DeltaWave Nasal Pillow System, and obtaining PDAC coding approval for Medicare reimbursement. His legacy is embodied in the DeltaWave technology and the company's mission to bring it to market.
Jeffrey Marshall, appointed as the new CEO and Director, brings extensive industry experience in sales, marketing, and commercial strategy. He has served as a strategy consultant to REMSleep since September 2025. Marshall stated that the immediate priorities are to execute the commercial opportunity Wood created, focusing on revenue generation through strategic sales and marketing plans to gain brand awareness and build partnerships with Durable Medical Equipment providers, physicians, and sleep labs. The leadership transition, including board formation and CEO appointment, was planned prior to Wood's passing to ensure the company's resilience.
The DeltaWave Nasal Pillow System, now commercially available, represents the first product in a planned broader portfolio. The company's strategic roadmap includes enhancing its product offerings and exploring applications of Wood's patented technologies for other chronic respiratory and neurological diseases, reflecting his original broader vision. For more information on the company, visit https://www.REMSleep.com.
This transition underscores the importance of succession planning in technology-driven medical businesses. For industry leaders, it highlights how foundational innovation, when coupled with strategic governance, can sustain a company's mission beyond its founder. The commercialization of DeltaWave could impact the sleep apnea treatment market by introducing a new, patient-centered option, potentially improving care standards and competitive dynamics. The company's ability to execute its commercial strategy will be closely watched by investors and healthcare providers alike.
